Technical Analysis for MYOV - Myovant Sciences Ltd.

Grade Last Price % Change Price Change
grade F 6.06 -1.94% -0.12
MYOV closed down 1.94 percent on Thursday, September 19, 2019, on 1.28 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical MYOV trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness -1.94%
Inside Day Range Contraction -1.94%
Wide Bands Range Expansion -1.94%
Lower Bollinger Band Touch Weakness -1.94%
Oversold Stochastic Weakness -1.94%
Volume Surge Other -0.66%
Lower Bollinger Band Walk Weakness -0.66%

Older signals for MYOV ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health diseases and other endocrine-related disorders. Its lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The company also intends to develop RVT-602, an oligopeptide kisspeptin analog, for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. was founded in 2016 and is based in Hamilton, Bermuda. Myovant Sciences Ltd. operates as a subsidiary of Roivant Sciences Ltd.
Chemistry Biopharmaceutical Pain Prostate Cancer Endocrine System Hormones Amines Pyrimidines Gnrh Antagonists Gonadotropin Releasing Hormone Antagonist Roivant Sciences Uterine Fibroids
Is MYOV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 27.45
52 Week Low 5.55
Average Volume 318,619
200-Day Moving Average 14.7595
50-Day Moving Average 7.4923
20-Day Moving Average 7.2545
10-Day Moving Average 6.546
Average True Range 0.5053
ADX 30.83
+DI 10.5931
-DI 29.3914
Chandelier Exit (Long, 3 ATRs ) 7.183299999999999
Chandelier Exit (Short, 3 ATRs ) 7.0659
Upper Bollinger Band 8.8683
Lower Bollinger Band 5.6407
Percent B (%b) 0.13
BandWidth 44.491006
MACD Line -0.454
MACD Signal Line -0.3014
MACD Histogram -0.1525
Fundamentals Value
Market Cap 368.71 Million
Num Shares 60.8 Million
EPS -1.63
Price-to-Earnings (P/E) Ratio -3.72
Price-to-Sales 0.00
Price-to-Book 5.51
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.62
Resistance 3 (R3) 6.61 6.42 6.52
Resistance 2 (R2) 6.42 6.28 6.42 6.49
Resistance 1 (R1) 6.24 6.19 6.15 6.25 6.46
Pivot Point 6.05 6.05 6.00 6.05 6.05
Support 1 (S1) 5.87 5.91 5.78 5.88 5.66
Support 2 (S2) 5.68 5.82 5.68 5.63
Support 3 (S3) 5.50 5.68 5.60
Support 4 (S4) 5.51